Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.

Ustun C, Kim S, Chen M, Beitinjaneh AM, Brown VI, Dahi PB, Daly A, Diaz MA, Freytes CO, Ganguly S, Hashmi S, Hildebrandt GC, Lazarus HM, Nishihori T, Olsson RF, Page KM, Papanicolaou G, Saad A, Seo S, William BM, Wingard JR, Wirk B, Yared JA, Perales MA, Auletta JJ, Komanduri KV, Lindemans CA, Riches ML.

Blood Adv. 2019 Sep 10;3(17):2525-2536. doi: 10.1182/bloodadvances.2019000226.

2.

Hematopoietic Cell Transplant-Related Toxicities and Mortality in Frail Recipients.

Pamukcuoglu M, Bhatia S, Weisdorf DJ, DeFor TE, Ustun C, Nayar M, Holtan SG, Jurdi NE, Thyagarajan B, Brunstein CG, Bachanova V, Warlick ED, Severseike B, Te HS, Lund T, Arora M.

Biol Blood Marrow Transplant. 2019 Aug 5. pii: S1083-8791(19)30502-6. doi: 10.1016/j.bbmt.2019.07.030. [Epub ahead of print]

PMID:
31394273
3.

Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease.

Holtan SG, Shabaneh A, Betts BC, Rashidi A, MacMillan ML, Ustun C, Amin K, Vaughn BP, Howard J, Khoruts A, Arora M, DeFor TE, Johnson D, Blazar BR, Weisdorf DJ, Wang J.

JCI Insight. 2019 Aug 8;5. pii: 129762. doi: 10.1172/jci.insight.129762.

4.

Locking plate fixation versus antegrade intramedullary nailing for the treatment of extra-articular distal femoral fractures.

Ocalan E, Ustun CC, Aktuglu K.

Injury. 2019 Jul 22. pii: S0020-1383(19)30407-3. doi: 10.1016/j.injury.2019.07.008. [Epub ahead of print]

PMID:
31378542
5.

Necessity for treatment of steroid refractory severe GIT GVHD: patience of providers.

Ustun C, Baptista J, Marinovic DA, Tollkuci E, Mozer M, Rashidi A, Weber M, Mutlu E, Holtan S, Weisdorf D, Nathan S.

Bone Marrow Transplant. 2019 Jul 29. doi: 10.1038/s41409-019-0630-1. [Epub ahead of print] No abstract available.

PMID:
31358917
6.

Is Haploidentical HCT Better Than…? A Wrong Question for Future Studies.

Ustun C.

Biol Blood Marrow Transplant. 2019 Jul 18. pii: S1083-8791(19)30452-5. doi: 10.1016/j.bbmt.2019.07.020. [Epub ahead of print] No abstract available.

PMID:
31326609
7.

Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.

Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT.

Transpl Infect Dis. 2019 Jul 12:e13145. doi: 10.1111/tid.13145. [Epub ahead of print]

PMID:
31301099
8.

Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.

Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, Zhang MJ, Storrick E, Lafky JM, Chow S, Mrózek K, Attar EC, Nand S, Bloomfield CD, Cripe LD, Tallman MS, Appelbaum F, Larson RA, Marcucci G, Roboz GJ, Uy GL, Stone RM, Jatoi A, Shea TC, de Lima M, Foran JM, Sandmaier BM, Litzow MR, Erba HP, Hurria A, Weisdorf DJ, Artz AS.

Leukemia. 2019 May 9. doi: 10.1038/s41375-019-0477-x. [Epub ahead of print]

PMID:
31073153
9.

Complications of Stem Cell Transplantation that Affect Infections in Stem Cell Transplant Recipients, with Analogies to Patients with Hematologic Malignancies.

Nathan S, Ustun C.

Infect Dis Clin North Am. 2019 Jun;33(2):331-359. doi: 10.1016/j.idc.2019.01.002. Epub 2019 Mar 30. Review.

PMID:
30940464
10.

Information Needs for Treatment Decision-making of Hematopoietic Cell Transplant Patients 65 Years or Older and Caregivers.

Foster J, Moore H, Preussler JM, Burns LJ, Umar JH, Glotzbecker B, Johnson S, MacDougall H, Mau LW, Murphy EA, Ustun C, Ferguson SS, Denzen E.

J Cancer Educ. 2019 Mar 15. doi: 10.1007/s13187-019-01506-5. [Epub ahead of print]

PMID:
30877651
11.

Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study.

Abidi MZ, Hari P, Chen M, Kim S, Battiwala M, Dahi PB, Diaz MA, Gale RP, Ganguly S, Gergis U, Green J, Hildebrandt G, Hill JA, Komanduri K, Lazarus H, Marks D, Nishihori T, Olsson R, Seo S, Ustun C, Yared J, Yin D, Wingard J, Wirk BM, Auletta J, Lindemans C, Riches M.

Bone Marrow Transplant. 2019 Aug;54(8):1354-1360. doi: 10.1038/s41409-019-0457-9. Epub 2019 Jan 29.

PMID:
30696997
12.

Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation.

Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Ustun C, Warlick ED, Arora M, Wagner JE, Weisdorf DJ.

Blood Adv. 2019 Feb 12;3(3):230-236. doi: 10.1182/bloodadvances.2018018549.

13.

Bloodstream infection (BSI) due to Vancomycin-Resistant Enterococcus (VRE) is associated with increased mortality after hematopoietic cell transplantation for acute leukemia and myelodysplastic syndrome: A multicenter, retrospective cohort study.

Papanicolaou GA, Ustun C, Young JH, Chen M, Kim S, Ahn KW, Komanduri K, Lindemans C, Auletta JJ, Riches ML; CIBMTR® Infection and Immune Reconstitution Working Committee.

Clin Infect Dis. 2019 Jan 14. doi: 10.1093/cid/ciz031. [Epub ahead of print]

PMID:
30649224
14.

Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation.

Ustun C, Young JH, Papanicolaou GA, Kim S, Ahn KW, Chen M, Abdel-Azim H, Aljurf M, Beitinjaneh A, Brown V, Cerny J, Chhabra S, Kharfan-Dabaja MA, Dahi PB, Daly A, Dandoy CE, Dvorak CC, Freytes CO, Hashmi S, Lazarus H, Ljungman P, Nishihori T, Page K, Pingali SRK, Saad A, Savani BN, Weisdorf D, Williams K, Wirk B, Auletta JJ, Lindemans CA, Komanduri K, Riches M.

Bone Marrow Transplant. 2019 Aug;54(8):1254-1265. doi: 10.1038/s41409-018-0401-4. Epub 2018 Dec 13.

15.

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W.

Blood Adv. 2018 Nov 13;2(21):2922-2936. doi: 10.1182/bloodadvances.2018024844.

16.

Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission.

How J, Vij KR, Ebadi M, DeFor TE, Romee R, Dolan MM, Ustun C, Weisdorf DJ, Linden MA, Rashidi A.

Am J Hematol. 2018 Dec;93(12):E381-E383. doi: 10.1002/ajh.25262. Epub 2018 Oct 9. No abstract available.

PMID:
30144151
17.

Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).

Ustun C, Morgan E, Moodie EEM, Pullarkat S, Yeung C, Broesby-Olsen S, Ohgami R, Kim Y, Sperr W, Vestergaard H, Chen D, Kluin PM, Dolan M, Mrózek K, Czuchlewski D, Horny HP, George TI, Kristensen TK, Ku NK, Yi CA, Møller MB, Marcucci G, Baughn L, Schiefer AI, Hilberink JR, Pullarkat V, Shanley R, Kohlschmidt J, Coulombe J, Salhotra A, Soma L, Cho C, Linden MA, Akin C, Gotlib J, Hoermann G, Hornick J, Nakamura R, Deeg J, Bloomfield CD, Weisdorf D, Litzow MR, Valent P, Huls G, Perales MA, Borthakur G.

Cancer Med. 2018 Sep;7(9):4447-4455. doi: 10.1002/cam4.1733. Epub 2018 Aug 16.

18.

Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up.

Warlick ED, DeFor TE, Bejanyan N, Holtan S, MacMillan M, Blazar BR, Dusenbery K, Arora M, Bachanova V, Cooley S, Lazaryan A, McGlave P, Miller JS, Rashidi A, Slungaard A, Vercellotti G, Ustun C, Brunsein C, Weisdorf D.

Biol Blood Marrow Transplant. 2019 Jan;25(1):56-62. doi: 10.1016/j.bbmt.2018.07.038. Epub 2018 Aug 1.

PMID:
30077015
19.

Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics.

Keklik F, Alrawi EB, Cao Q, Bejanyan N, Rashidi A, Lazaryan A, Arndt P, Dincer EH, Bachanova V, Warlick ED, MacMillan ML, Arora M, Miller J, Brunstein CG, Weisdorf DJ, Ustun C.

Haematologica. 2018 Dec;103(12):2109-2115. doi: 10.3324/haematol.2018.189134. Epub 2018 Aug 3.

20.

Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation.

Hegerova L, Bachan A, Cao Q, Vu HX, Rogosheske J, Reding MT, Brunstein CG, Arora M, Ustun C, Vercellotti GM, Bachanova V.

Biol Blood Marrow Transplant. 2018 Dec;24(12):e20-e25. doi: 10.1016/j.bbmt.2018.07.028. Epub 2018 Jul 25.

PMID:
30053647
21.

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells.

Yun HD, Felices M, Vallera DA, Hinderlie P, Cooley S, Arock M, Gotlib J, Ustun C, Miller JS.

Blood Adv. 2018 Jul 10;2(13):1580-1584. doi: 10.1182/bloodadvances.2018018176. No abstract available.

22.
23.

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.

Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA, Miller JS.

Blood. 2018 Jun 7;131(23):2515-2527. doi: 10.1182/blood-2017-12-823757. Epub 2018 Feb 20.

24.

Practices in Human Dignity in Palliative Care: A Qualitative Study.

Akin Korhan E, Üstün Ç, Uzelli Yilmaz D.

Holist Nurs Pract. 2018 Mar/Apr;32(2):71-80. doi: 10.1097/HNP.0000000000000252.

PMID:
29432353
25.

A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia.

He F, Sapkota S, Parker S, Defor T, Warlick E, Ustun C, Eckfeldt C, Rashidi A, Kurtzweil A, Weisdorf D, Bejanyan N.

Leuk Lymphoma. 2018 Oct;59(10):2352-2359. doi: 10.1080/10428194.2018.1433297. Epub 2018 Feb 7.

PMID:
29415603
26.

Concomitant cutaneous squamous cell carcinoma and chronic lymphocytic leukemia in a patient: The utility of 18 F-FDG PET/CT in differentiation of nodal metastasis.

Ozturk K, Ustun C, Khaja S, Li F, Rischall M, Cayci Z.

Am J Hematol. 2018 Aug;93(4):597-598. doi: 10.1002/ajh.25041. Epub 2018 Feb 14. No abstract available.

27.

Impending relapse of myelodysplastic syndrome after allogeneic transplant is difficult to diagnose and requires a multi-modal approach.

Courville EL, Griffith M, Ustun C, Yohe S, Warlick E.

BMC Clin Pathol. 2017 Dec 28;17:28. doi: 10.1186/s12907-017-0066-8. eCollection 2017.

28.

The challenges of treating aspergillus abdominal aneurysm after hematopoietic cell transplant: Rapid voriconazole metabolizer.

Wasko JA, Ustun C, Birkenbach M, Faizer R, Green JS.

J Oncol Pharm Pract. 2019 Apr;25(3):703-705. doi: 10.1177/1078155217748471. Epub 2017 Dec 29.

PMID:
29285995
29.

Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.

Bejanyan N, Zhang MJ, Wang HL, Lazaryan A, de Lima M, Marks DI, Sandmaier BM, Bachanova V, Rowe J, Tallman M, Kebriaei P, Kharfan-Dabaja M, Peter Gale R, Lazarus HM, Ustun C, Copelan E, Ky Hamilton B, Schiller G, Hogan W, Hashmi S, Seftel M, Kanakry CG, Olsson RF, Martino R, Saber W, Khoury HJ, Weisdorf DJ.

Biol Blood Marrow Transplant. 2018 May;24(5):945-955. doi: 10.1016/j.bbmt.2017.12.784. Epub 2017 Dec 21.

30.

UCB HCT in FLT3+ AML.

Ustun C, Ruggeri A, Weisdorf DJ.

Oncotarget. 2017 Sep 19;8(47):81733-81734. doi: 10.18632/oncotarget.21048. eCollection 2017 Oct 10. No abstract available.

31.

Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.

Hill BT, Ahn KW, Hu ZH, Aljurf M, Beitinjaneh A, Cahn JY, Cerny J, Kharfan-Dabaja MA, Ganguly S, Ghosh N, Grunwald MR, Inamoto Y, Kindwall-Keller T, Nishihori T, Olsson RF, Saad A, Seftel M, Seo S, Szer J, Tallman M, Ustun C, Wiernik PH, Maziarz RT, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W.

Biol Blood Marrow Transplant. 2018 Mar;24(3):581-586. doi: 10.1016/j.bbmt.2017.10.015. Epub 2017 Oct 12.

32.

Importance of conditioning regimen intensity, MRD positivity, and KIR ligand mismatch in UCB transplantation.

Ustun C, Brunstein C, DeFor T, Rashidi A, Yohe S, Bejanyan N, Cooley S, Warlick E, Miller J, Linden MA, Weisdorf D.

Bone Marrow Transplant. 2018 Jan;53(1):97-100. doi: 10.1038/bmt.2017.212. Epub 2017 Oct 9. No abstract available.

PMID:
28991246
33.

Time-to-Event Ratio to Predict Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation?

Ustun C, DeFor TE, Rashidi A, Devine S, Miller J, Weisdorf D.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1804-1808. doi: 10.1016/j.bbmt.2017.06.016. Epub 2017 Jul 5. No abstract available.

34.

History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.

Rashidi A, Linden MA, DeFor TE, Warlick E, Bejanyan N, Yohe S, Weisdorf DJ, Ustun C.

Am J Hematol. 2017 Oct;92(10):1032-1036. doi: 10.1002/ajh.24834. Epub 2017 Jul 29.

35.

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M.

Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Lancet Oncol. 2018 Jul;19(7):e335. Lancet Oncol. 2019 Jun;20(6):e293.

36.

Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients.

Belete H, Burns LJ, Shanley R, Nayar M, McClune B, Lazaryan A, Bachanova V, Bejanyan N, Ustun C, Brunstein C, Weisdorf DJ, Arora M.

Am J Hematol. 2017 Sep;92(9):E529-E533. doi: 10.1002/ajh.24814. Epub 2017 Jul 19.

37.

Genomics of clonal evolution in a case of essential thrombocythemia.

Rashidi A, Nelson AC, Linden MA, Weisdorf DJ, Dolan MM, Ustun C.

Leuk Lymphoma. 2018 Feb;59(2):497-500. doi: 10.1080/10428194.2017.1337113. Epub 2017 Jun 11. No abstract available.

PMID:
28604261
38.

Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.

Rashidi A, Ali AM, Vij KR, Shanley R, Romee R, Cooley SA, Westervelt P, DiPersio JF, Miller JS, Weisdorf DJ, Ustun C.

Am J Hematol. 2017 Sep;92(9):E549-E552. doi: 10.1002/ajh.24804. Epub 2017 Jul 19. Review. No abstract available.

39.

Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index.

He F, Cao Q, Lazaryan A, Brunstein C, Holtan S, Warlick E, Ustun C, McClune B, Arora M, Rashidi A, Eckfeldt C, Weisdorf DJ, Bejanyan N.

Biol Blood Marrow Transplant. 2017 Sep;23(9):1485-1490. doi: 10.1016/j.bbmt.2017.05.012. Epub 2017 May 15.

40.

Dose Escalation of Total Marrow Irradiation in High-Risk Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Hui S, Brunstein C, Takahashi Y, DeFor T, Holtan SG, Bachanova V, Wilke C, Zuro D, Ustun C, Weisdorf D, Dusenbery K, Verneris MR.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1110-1116. doi: 10.1016/j.bbmt.2017.04.002. Epub 2017 Apr 7.

41.

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.

Gerds AT, Woo Ahn K, Hu ZH, Abdel-Azim H, Akpek G, Aljurf M, Ballen KK, Beitinjaneh A, Bacher U, Cahn JY, Chhabra S, Cutler C, Daly A, DeFilipp Z, Gale RP, Gergis U, Grunwald MR, Hale GA, Hamilton BK, Jagasia M, Kamble RT, Kindwall-Keller T, Nishihori T, Olsson RF, Ramanathan M, Saad AA, Solh M, Ustun C, Valcárcel D, Warlick E, Wirk BM, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W.

Biol Blood Marrow Transplant. 2017 Jun;23(6):971-979. doi: 10.1016/j.bbmt.2017.03.014. Epub 2017 Mar 10.

42.

Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.

Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, Sotlar K, Sperr WR, Escribano L, George TI, Kluin-Nelemans HC, Ustun C, Triggiani M, Brockow K, Gotlib J, Orfao A, Schwartz LB, Broesby-Olsen S, Bindslev-Jensen C, Kovanen PT, Galli SJ, Austen KF, Arber DA, Horny HP, Arock M, Metcalfe DD.

Cancer Res. 2017 Mar 15;77(6):1261-1270. doi: 10.1158/0008-5472.CAN-16-2234. Epub 2017 Mar 2. Review.

43.

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source.

Damodar S, Shanley R, MacMillan M, Ustun C, Weisdorf D.

Biol Blood Marrow Transplant. 2017 May;23(5):795-804. doi: 10.1016/j.bbmt.2017.02.009. Epub 2017 Feb 14.

44.

Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia.

Ustun C, Williams S, Skendzel S, Kodal B, Arock M, Gotlib J, Vallera DA, Cooley S, Felices M, Weisdorf D, Miller J.

Am J Hematol. 2017 May;92(5):E66-E68. doi: 10.1002/ajh.24673. Epub 2017 Feb 24. No abstract available.

45.

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.

Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, DeFor TE, Malagola M, Anthias C, Valkova V, Kanakry CG, Gruhn B, Buccisano F, Devine B, Walter RB.

Haematologica. 2017 May;102(5):865-873. doi: 10.3324/haematol.2016.159343. Epub 2017 Jan 25. Review.

46.

Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.

Ustun C, Giannotti F, Zhang MJ, Wang HL, Brunstein C, Labopin M, Rocha V, de Lima M, Baron F, Sandmaier BM, Eapen M, Gluckman E, Nagler A, Weisdorf DJ, Ruggeri A.

Leukemia. 2017 Jun;31(6):1408-1414. doi: 10.1038/leu.2017.42. Epub 2017 Jan 25.

47.

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.

Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR, Sabloff M, Olsson RF, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks DI, Copelan E, Gergis U, Savoie ML, Ustun C, Litzow MR, Cahn JY, Kindwall-Keller T, Akpek G, Savani BN, Aljurf M, Rowe JM, Wiernik PH, Hsu JW, Cortes J, Kalaycio M, Maziarz R, Sobecks R, Popat U, Alyea E, Saber W.

Biol Blood Marrow Transplant. 2017 May;23(5):767-775. doi: 10.1016/j.bbmt.2017.01.078. Epub 2017 Jan 20.

48.

Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.

El-Jawahri A, Chen YB, Brazauskas R, He N, Lee SJ, Knight JM, Majhail N, Buchbinder D, Schears RM, Wirk BM, Wood WA, Ahmed I, Aljurf M, Szer J, Beattie SM, Battiwalla M, Dandoy C, Diaz MA, D'Souza A, Freytes CO, Gajewski J, Gergis U, Hashmi SK, Jakubowski A, Kamble RT, Kindwall-Keller T, Lazarus HM, Malone AK, Marks DI, Meehan K, Savani BN, Olsson RF, Rizzieri D, Steinberg A, Speckhart D, Szwajcer D, Schoemans H, Seo S, Ustun C, Atsuta Y, Dalal J, Sales-Bonfim C, Khera N, Hahn T, Saber W.

Cancer. 2017 May 15;123(10):1828-1838. doi: 10.1002/cncr.30546. Epub 2017 Jan 19.

49.

Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study.

Maziarz RT, Brazauskas R, Chen M, McLeod AA, Martino R, Wingard JR, Aljurf M, Battiwalla M, Dvorak CC, Geroge B, Guinan EC, Hale GA, Lazarus HM, Lee JW, Liesveld JL, Ramanathan M, Reddy V, Savani BN, Smith FO, Strasfeld L, Taplitz RA, Ustun C, Boeckh MJ, Gea-Banacloche J, Lindemans CA, Auletta JJ, Riches ML.

Bone Marrow Transplant. 2017 Feb;52(2):270-278. doi: 10.1038/bmt.2016.259. Epub 2016 Dec 19.

50.

MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes.

Pourhassan H, DeFor T, Trottier B, Dolan M, Brunstein C, Bejanyan N, Ustun C, Warlick ED.

Bone Marrow Transplant. 2017 Apr;52(4):532-538. doi: 10.1038/bmt.2016.303. Epub 2016 Dec 12.

Supplemental Content

Support Center